Rukobia Tablet, Film Coated, Extended Release
Product Images NDC 49702-250

Product Visual Gallery

This gallery contains 2 technical images submitted to the FDA as part of the official labeling for Rukobia (NDC 49702-250). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Viiv Healthcare Company, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fostemsavir Tromethamine Chemical Structure (Rukobia Spl Graphic 01)

Chemical structure of fostemsavir tromethamine, the active ingredient in Rukobia 600 mg extended-release oral tablets from ViiV Healthcare Company.*

FDA Label Image

Rukobia 600 mg 60 Count Carton (Rukobia Spl Graphic 02)

Label of Rukobia 600 mg extended-release film-coated tablets, containing fostemsavir. The label states each tablet has 600 mg of fostemsavir (equivalent to 725 mg fostemsavir tromethamine). Packaged as a bottle of 60 tablets. The label includes the ViiV Healthcare logo and a pharmacist alert about medicines that should not be taken with Rukobia.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.